Aadvac1 Tau Vaccine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
AADvac1 is an active immunotherapy vaccine targeting pathological tau protein, developed by Axon Neuroscience SE for the treatment of Alzheimer's disease and other tauopathies. It represents a novel disease-modifying approach aimed at clearing or preventing the formation of neurofibrillary tangles.
| Property |
Value |
| Category |
Treatments |
| Target |
Pathological tau protein |
| Approach |
Active immunotherapy (vaccine) |
| Status |
Phase II clinical trials |
| Developer |
Axon Neuroscience SE |
AADvac1 is a synthetic peptide vaccine designed to elicit antibodies against specific epitopes of pathological tau protein:
- Immunogen: Synthetic tau peptide conjugated to keyhole limpet hemocyanin (KLH)
- Target epitopes: Phosphorylated tau residues (particularly pSer396, pSer404)
- Adjuvant: Proprietary formulation for enhanced immune response
¶ Antibody Generation
Upon administration, AADvac1 stimulates the immune system to produce antibodies that:
- Recognize pathological tau: Antibodies specifically bind to phosphorylated tau aggregates
- Clear extracellular tau: Facilitate removal of toxic tau species
- Block tau spreading: Prevent inter-neuronal transmission of tau pathology
- Reduce tau oligomers: Target soluble toxic oligomers before they aggregate
The vaccine targets multiple forms of pathological tau:
- Hyperphosphorylated tau
- Tau oligomers
- Paired helical filaments
- Neurofibrillary tangles
- Randomized, placebo-controlled
- Multiple dose cohorts
- Healthy volunteers and AD patients
- Safe and well-tolerated
- Robust antibody response in majority of participants
- Antibodies detected in CSF (key finding)
- Reduced tau pathology in some subjects
- 196 patients with mild-to-moderate AD
- Randomized 1:1 to AADvac1 or placebo
- 24-month treatment period
- Primary endpoint: safety and tolerability
- Met primary safety endpoint
- Significant reduction in neurofibrillary tangles (tau PET)
- Slower cognitive decline in biomarker-positive subgroup
- Antibody responders showed better outcomes
- Reduced CSF total tau and phospho-tau
- Tau PET signal reduction in treatment group
- Lower rates of brain atrophy in responders
- Modified Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
- Clinical Dementia Rating Sum of Boxes (CDR-SB)
- Disability Assessment for Dementia (DAD)
- Patients with confirmed tau pathology benefited most
- Earlier treatment showed better outcomes
- Antibody titer correlated with efficacy
- Injection site reactions (mild)
- Headache
- Fatigue
- No increase vs placebo
- No autoimmune encephalitis cases
- No ARIA (Amyloid-Related Imaging Abnormalities)
- High responder rate (>80%)
- Consistent antibody titers
- Long-term persistence
¶ Competitive Landscape
| Vaccine |
Type |
Status |
Key Features |
| AADvac1 |
Active |
Phase II |
Tau pSer396/404 |
| ACI-35 |
Active |
Phase I |
Phospho-tau liposomal |
| BMS-986036 |
Passive |
Phase II |
Anti-tau antibody |
- Long-lasting immunity
- Lower treatment burden
- Potential for disease modification
- Cost-effective
¶ Challenges and Limitations
¶ Antibody Penetration
- Limited CNS penetration
- Effector mechanisms in brain unclear
- Need for better understanding of mechanism
- Biomarkers needed to identify responders
- Optimal treatment timing unclear
- Disease stage matters
- Consistent vaccine production
- Quality control
- Scalability
- Phase III registration trials
- Combination approaches
- Earlier intervention studies
- Improved epitopes
- Enhanced brain penetration
- Better adjuvant systems
- Tau PET for patient selection
- Antibody titer monitoring
- CSF biomarker panels
The study of Aadvac1 Tau Vaccine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Novak P, et al. (2019). Safety and immunogenicity of the tau vaccine AADvac1: a randomized, double-blind, placebo-controlled, first-in-human study. Alzheimer's Research & Therapy. 11(1):32.
- Novak P, et al. (2021). ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1 in Alzheimer's disease. Alzheimer's Research & Therapy. 13(1):90.
- Kontsekova E, et al. (2014). First-in-man tau vaccine: structural rationale and results from first-in-human trial. CNS Drugs. 28(12):1195-1209.
- Zilkova M, et al. (2020). Tau targeting vaccines for Alzheimer's disease and related tauopathies. Journal of Immunology Research. 2020:1470783.
- Sigurdsson EM. (2016). Tau immunotherapy. Neurodegenerative Diseases. 16(1-2):29-34.
- Boutajangout A, et al. (2010). Vaccination as a therapeutic approach to Alzheimer's disease: Mounting evidence. Neurochemical Research. 35(2):211-220.
- Cohen M, et al. (2021). Anti-tau antibody administration reduces tau pathology and improves cognition in mouse models. Journal of Experimental Medicine. 218(8).
- Chernyak S, et al. (2021). Clinical development of anti-tau antibodies in Alzheimer's disease: current status and future prospects. Neurology and Therapy. 10(2):503-516.